A Non-therapeutic Feasibility Study to Evaluate the Kinetics and Test-retest Repeatability and Reproducibility of the Radioligand [11C]-UCB-J for Imaging Synaptic Density in Healthy Subjects and Mild-to-moderate Alzheimer's Disease Subjects
Phase of Trial: Phase 0
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Carbon 11 UCB J (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Rodin Therapeutics
- 09 Sep 2019 Status changed from recruiting to completed.
- 25 Jun 2019 According to a Rodin Therapeutics media release,data from this study will be presented at the upcoming Alzheimer's Association International Conference (AAIC) meeting in Los Angeles on July 14-18.
- 25 Mar 2019 Planned End Date changed from 20 Mar 2019 to 20 May 2019.